[go: up one dir, main page]

AR038535A1 - Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos - Google Patents

Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos

Info

Publication number
AR038535A1
AR038535A1 ARP030100551A ARP030100551A AR038535A1 AR 038535 A1 AR038535 A1 AR 038535A1 AR P030100551 A ARP030100551 A AR P030100551A AR P030100551 A ARP030100551 A AR P030100551A AR 038535 A1 AR038535 A1 AR 038535A1
Authority
AR
Argentina
Prior art keywords
prepare
processes
pharmaceutical formulations
pharmaceutical formulation
antineoplasic agents
Prior art date
Application number
ARP030100551A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27766051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038535(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR038535A1 publication Critical patent/AR038535A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formulación farmacéutica que comprende al menos un agente antineoplásico o una sal farmacéuticamente aceptable del mismo y al menos un agente mejorador de la disolución suficiente para disolver sustancialmente el agente antineoplásico en al menos un diluyente acuoso, donde el agente mejorador de la disolución es urea, L-histidina, L-treonina, L-asparragina, L-serina, L-glutamina o mezclas de las mismas; un polvo liofilizado que comprende la formulación farmacéutica, y artículos de manufactura de los mismos. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 2, donde el agente antineoplásico es temozolomida.
ARP030100551A 2002-02-22 2003-02-20 Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos AR038535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35919802P 2002-02-22 2002-02-22

Publications (1)

Publication Number Publication Date
AR038535A1 true AR038535A1 (es) 2005-01-19

Family

ID=27766051

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP030100551A AR038535A1 (es) 2002-02-22 2003-02-20 Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
ARP080100003A AR064722A2 (es) 2002-02-22 2008-01-02 Procesos para preparar formulaciones farmaceuticas de agentes antineoplasicos, polvo liofilizado, articulo que lo comprende y formulacion farmaceutica
ARP120100145A AR084868A2 (es) 2002-02-22 2012-01-16 Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP080100003A AR064722A2 (es) 2002-02-22 2008-01-02 Procesos para preparar formulaciones farmaceuticas de agentes antineoplasicos, polvo liofilizado, articulo que lo comprende y formulacion farmaceutica
ARP120100145A AR084868A2 (es) 2002-02-22 2012-01-16 Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos

Country Status (23)

Country Link
US (9) US6987108B2 (es)
EP (1) EP1478339B9 (es)
JP (2) JP4077794B2 (es)
KR (1) KR100970528B1 (es)
CN (2) CN101172104B (es)
AR (3) AR038535A1 (es)
AT (1) ATE397440T1 (es)
AU (1) AU2003213142B2 (es)
BR (1) BRPI0307802B8 (es)
CA (2) CA2662899A1 (es)
CY (1) CY1108291T1 (es)
DE (1) DE60321450D1 (es)
DK (1) DK1478339T3 (es)
ES (1) ES2307905T3 (es)
MX (1) MXPA04008133A (es)
NO (1) NO335045B1 (es)
NZ (1) NZ534378A (es)
PL (1) PL205936B1 (es)
PT (1) PT1478339E (es)
SG (1) SG161101A1 (es)
SI (1) SI1478339T1 (es)
WO (1) WO2003072082A1 (es)
ZA (1) ZA200406632B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038535A1 (es) * 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
AU2005232583B2 (en) * 2004-04-01 2009-03-12 Teva Pharmaceutical Industries Ltd. Delayed release formulations of 6-mercaptopurine
JP2008521911A (ja) * 2004-12-02 2008-06-26 シェーリング コーポレイション 癌の処置において髄腔内にテモゾロミド処方物を使用する方法
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
US20100119592A1 (en) * 2006-12-08 2010-05-13 Bruce Michael Frankel Cytarabine for treatment of glioma
FR2910812B1 (fr) * 2006-12-29 2009-03-20 Pierre Fabre Medicament Sa Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
US20100210700A1 (en) * 2007-05-08 2010-08-19 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
US20080319039A1 (en) * 2007-06-25 2008-12-25 Jacqueline Rose Bersch Unit dosage forms of temozolomide
CN101467967B (zh) * 2007-12-29 2012-05-23 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN101559037B (zh) * 2008-04-16 2013-01-30 北京京卫燕康药物研究所有限公司 用于静脉和脑内注射的两元溶液型制剂
CA2721728A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
AR066943A1 (es) * 2008-06-10 2009-09-23 Eriochem Sa Una composicion farmaceutica de melfalano
JP5775452B2 (ja) 2008-07-10 2015-09-09 アンジオン バイオメディカ コーポレイション 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法
US8741972B2 (en) 2008-09-30 2014-06-03 Columbia Insurance Company Recycled polyethylene terephthalate compositions, fibers and articles produced therefrom, and methods for producing same
MX2009010614A (es) 2008-09-30 2010-04-30 Shaw Ind Group Inc Composiciones de tereftalato de polietileno reciclado, fibras y articulos producidos a partir de las mismas y metodos para producirlas.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2396000A1 (en) * 2009-02-11 2011-12-21 Bristol-Myers Squibb Company Combination vegfr2 therapy with temozolomide
WO2011036676A2 (en) 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
EP3091028A1 (en) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
CN101869551B (zh) * 2010-06-28 2012-04-18 江苏奥赛康药业股份有限公司 一种替莫唑胺冻干制剂
CN102342931B (zh) * 2010-07-29 2014-04-23 江苏恒瑞医药股份有限公司 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法
CN101984968A (zh) * 2010-10-29 2011-03-16 北京润德康医药技术有限公司 抗肿瘤剂替莫唑胺的药物制剂制备方法
CN102659789B (zh) * 2011-04-27 2014-10-15 四川科瑞德凯华制药有限公司 一锅法制备替莫唑胺的方法及替莫唑胺的精制方法
AU2012247545B2 (en) 2011-04-28 2016-08-11 Oncopeptides Innovation Ab Lyophilized preparation of cytotoxic dipeptides
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
CN102949351B (zh) * 2011-08-16 2015-05-13 上海汇伦生命科技有限公司 一种替莫唑胺冻干制剂的制备方法
CN102688202B (zh) * 2012-06-07 2013-08-14 北京莱瑞森医药科技有限公司 一种替莫唑胺冻干制剂
US8974811B2 (en) 2013-03-14 2015-03-10 Hikma Pharmaceuticals Stabilized pharmaceutical formulations comprising antineoplastic compounds
CN104274412A (zh) * 2013-07-01 2015-01-14 北京恒瑞康达医药科技发展有限公司 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂
CN103432085A (zh) * 2013-08-19 2013-12-11 南京海纳医药科技有限公司 一种含氨基酸增溶剂的替莫唑胺冻干制剂及其制备方法
DK2865391T3 (da) 2013-10-22 2017-11-20 Medac Ges Für Klinische Spezialpräparate Mbh Fremgangsmåde til fremstilling af en frysetørret farmaceutisk sammensætning indeholdende mitomycin C
EP3157576B1 (en) * 2014-06-20 2024-07-31 Syddansk Universitet Auger electron therapy for glioblastoma
MX386433B (es) * 2014-08-14 2025-03-18 L E A F Holdings Group Llc Fármaco de afinidad encapsulado en liposoma.
MX391152B (es) 2015-01-14 2025-03-21 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
PL3452017T3 (pl) * 2016-05-02 2020-08-10 Double Bond Pharmaceutical AB Trwała przeciwnowotworowa kompozycja farmaceutyczna zawierająca temozolomid i sposób wytwarzania kompozycji
JP6706988B2 (ja) * 2016-07-20 2020-06-10 日本化薬株式会社 ボルテゾミブを含有する医薬組成物
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
CN107213123A (zh) * 2017-07-23 2017-09-29 南京正宽医药科技有限公司 一种注射用盐酸氨溴索及其制备方法
BE1025934B1 (fr) * 2018-01-12 2020-05-05 Hyloris Dev Sa Suspension pharmaceutique de méthylprednisolone
JP2022526827A (ja) 2019-04-11 2022-05-26 アンジオン バイオメディカ コーポレーション （ｅ）－３－［２－（２－チエニル）ビニル］－１ｈ－ピラゾールの固体形態
EP4065108B1 (en) 2019-11-25 2025-08-06 The Johns Hopkins University Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
WO2021229442A1 (en) 2020-05-12 2021-11-18 Shorla Pharma Ltd Stable formulations of temozolomide for oral administration
WO2024071464A1 (ko) * 2022-09-27 2024-04-04 (주)바이오솔릭스 말레이트 금속염을 포함하는 항암용 조성물
WO2025008797A1 (en) 2023-07-06 2025-01-09 Shorla Pharma Ltd Oral compositions comprising temozolomide or lenalidomide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US5260291A (en) * 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US5204335A (en) 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
JPS63313721A (ja) * 1987-06-17 1988-12-21 Teisan Seiyaku Kk 速溶性の注射用組成物
SU1479049A1 (ru) * 1987-07-01 1989-05-15 Научно-производственное объединение "Биолар" Способ получени концентрата водорастворимых фосфолипидов
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
JP2977236B2 (ja) * 1990-07-20 1999-11-15 株式会社東芝 音声合成装置
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
EP0922458A1 (en) * 1993-01-14 1999-06-16 Cancer Research Campaign Technology Limited Potentiation of temozolomide by an ATase inhibitor
DE4331147A1 (de) * 1993-09-14 1995-03-16 Nycomed Arzneimittel Gmbh Intravenös verabreichbare, wäßrige Lösung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
CZ302005B6 (cs) 1998-03-26 2010-09-01 Schering Corporation Vodný prostredek PEG-interferon alfa konjugátu, jeho lyofilizát a výrobek jej obsahující
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US5972912A (en) 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
WO2001047928A2 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinone und ihre verwendung
AR038535A1 (es) * 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
JP2008519584A (ja) * 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法

Also Published As

Publication number Publication date
NO335045B1 (no) 2014-09-01
CA2662899A1 (en) 2003-09-04
US20180078546A1 (en) 2018-03-22
EP1478339A1 (en) 2004-11-24
AR084868A2 (es) 2013-07-10
MXPA04008133A (es) 2004-11-26
PL205936B1 (pl) 2010-06-30
DE60321450D1 (de) 2008-07-17
US20060122163A1 (en) 2006-06-08
KR100970528B1 (ko) 2010-07-16
JP2008031186A (ja) 2008-02-14
JP2005518434A (ja) 2005-06-23
WO2003072082A1 (en) 2003-09-04
PL372319A1 (en) 2005-07-11
ES2307905T3 (es) 2008-12-01
US20160082005A1 (en) 2016-03-24
CA2476494A1 (en) 2003-09-04
US20190336495A1 (en) 2019-11-07
AU2003213142B2 (en) 2005-11-10
BRPI0307802B1 (pt) 2018-11-27
US7674790B2 (en) 2010-03-09
CN101172104A (zh) 2008-05-07
EP1478339B1 (en) 2008-06-04
NZ534378A (en) 2006-10-27
CA2476494C (en) 2010-04-27
PT1478339E (pt) 2008-09-05
SG161101A1 (en) 2010-05-27
DK1478339T3 (da) 2008-08-25
AU2003213142A1 (en) 2003-09-09
US7786118B2 (en) 2010-08-31
US20140088166A1 (en) 2014-03-27
US20040043001A1 (en) 2004-03-04
US20100331382A1 (en) 2010-12-30
JP4785816B2 (ja) 2011-10-05
CN101172104B (zh) 2013-04-03
US20090176852A1 (en) 2009-07-09
US8623868B2 (en) 2014-01-07
AR064722A2 (es) 2009-04-22
ATE397440T1 (de) 2008-06-15
BR0307802A (pt) 2004-12-21
HK1066466A1 (en) 2005-03-24
US8076335B2 (en) 2011-12-13
BRPI0307802B8 (pt) 2021-05-25
SI1478339T1 (sl) 2008-10-31
ZA200406632B (en) 2005-11-30
US20120053219A1 (en) 2012-03-01
EP1478339B9 (en) 2009-08-19
JP4077794B2 (ja) 2008-04-23
CN1635871A (zh) 2005-07-06
NO20043961L (no) 2004-09-21
KR20040085196A (ko) 2004-10-07
CN100346784C (zh) 2007-11-07
US6987108B2 (en) 2006-01-17
CY1108291T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
AR038535A1 (es) Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
AR018143A1 (es) Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
NO20053277D0 (no) Hurtigvirkende farmasoytisk sammensetning.
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
AR046510A1 (es) Composicion de un antagonista de vegf y un agente anti-proliferativo
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
PA8509001A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
BR0015605A (pt) Composição e uso
AR029471A1 (es) Forma cristalina de la sal de disodio del acido n- [4- [2-(2-amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil]benzoil] -l-glutrmico-forma cristalina heptahidrato-; procedimiento de uso de dicha forma en la fabricacion de medicamentos para el tratamiento del cancer; formulaciones farmaceu
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PE20010286A1 (es) Derivados de indoloxoacetil piperazina como agentes antivirales
WO2005065646A3 (en) Novel drug compositions and dosage forms
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR033688A1 (es) Composicion parenteral reconstituible
ES2080497T3 (es) Bloques para la limpieza de inodoros.
AR048050A1 (es) Formas de administracion masticables, no comprimidas, dosificadas individualmente
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
CO5241355A1 (es) Forma envasada de composiciones farmaceuticas nucleosidicas activas para vacunas contra la hepatitis

Legal Events

Date Code Title Description
FC Refusal